Poster: Primary Human Small Intestine Monolayers For Assessing Drug-Induced Intestinal Liabilities In Vitro

The RepliGut SOT 2023 poster, presented at the 2023 SOT meeting, features collaborators from Janssen Pharmaceuticals describing their use of the RepliGut® Planar Platform  to distinguish between compounds with different potencies for the JNJ epigenetic target X with a known in vivoGI liability. The poster describes testing a limited set of reference compounds including drugs with a high (> 50%) and a low (0-4%) incidence of diarrhea in the clinic.

https://www.altisbiosystems.com/wp-content/uploads/2023/09/JNJ_poster1_SOT2023.pdf

Ready to design your study?

Talk to our team
TLR Signaling in IBD Begins at the Epithelium

TLR Signaling in IBD Begins at the Epithelium

Posted by
Most of the excitement in inflammatory bowel disease right now points upstream. The field spent two decades blocking finished cytokines,…
Read More
Species Differences in Drug Absorption: The 63% That Became 3%

Species Differences in Drug Absorption: The 63% That Became 3%

Posted by
Here is a number that should stop any oral drug program cold. A compound absorbs at 63% in rats and…
Read More
Ester Prodrug Design for the Human Gut, Not the Cancer Line

Ester Prodrug Design for the Human Gut, Not the Cancer Line

Posted by
Ester prodrug design is an exercise in controlled instability. You start with a molecule that has a real liability: poor…
Read More